Homologous Recombination Deficiency (HRD) testing helps personalize treatment for ovarian cancer by identifying tumors with impaired DNA repair mechanisms. Patients with HRD-positive tumors, including those with BRCA1/2 mutations, may benefit from targeted therapies like PARP inhibitors. This test enables oncologists to tailor treatment plans, improve outcomes, and avoid unnecessary side effects.
30 days upon receipt of sample in the lab.
Webjet Acropolis, 88 Eulogio Rodriguez Jr. Ave, Quezon City, 1102 Metro Manila
Reminder: Your selected schedule is not yet final.
A Hati Health concierge will reach out to you for your final appointment details within 24 hours. You will receive a confirmation email once it's confirmed. Thank you for your patience.